Financial News
Articles published by Dyne Therapeutics, Inc.
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Dyne Therapeutics to Present at February Investor Conferences
February 01, 2024
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
January 04, 2024
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
January 03, 2024
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg)
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Dyne Therapeutics to Present at November Investor Conferences
November 07, 2023
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Dyne Therapeutics to Present at October Investor Conferences
September 28, 2023
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 20, 2023
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
Via GlobeNewswire
Tickers
DYN
![](https://ml.globenewswire.com/media/83dabff7-96e0-40c3-aa31-1401fbb3f776/small/dynelogo-final-color-cmyk-jpg.jpg)
Via GlobeNewswire
Tickers
DYN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.